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Cell cycle checkpoints are overcome by sequential activation of
cyclin-dependent kinases (CDKs), which are regulated in several
ways, including by binding with cyclins, sequestration of CDK
inhibitors, and phosphorylation on the CDKs themselves (Hunter
and Pines, 1994; Sherr, 1994). Phosphorylation on CDKs is func-
tionally classified as stimulatory phosphorylation on the tyrosine
residue by CAK (CDK-activating kinase) and inhibitory phos-
phorylation on threonine and tyrosine residues at the ATP binding
site. The latter is controlled by wee1 kinase and the CDC25 phos-
phatase family (Pines, 1995). Three members of the CDC25
family (CDC25A, B and C) are commonly characterized as cell
cycle oscillators in different phases of the cell cycle, in which both
CDC25B and CDC25C work at the G2/M checkpoint, and
CDC25A at the G1 checkpoint (Galaktionov and Beach, 1991;
Nagata et al, 1991; Sadhu et al, 1990). During carcinogenesis, both
CDC25A and CDC25B are over-expressed in various human
malignancies including non-Hodgkin’s lymphoma, breast cancer,
non-small cell lung cancer, and head and neck cancer, however, no
alteration of CDC25C has yet been reported (Galaktionov et al,
1995; Gasparotto et al, 1997; Hernandez et al, 1998; Wu et al,
1998). The potentiality of being an oncogene has been experimen-
tally demonstrated with CDC25A and CDC25B, which were
shown to transform murine fibroblasts in cooperation with mutated
Ha-ras or loss of Rb (retinoblastoma gene) (Galaktionov et al, 1995).
In addition, CDC25A is over-expressed in azoxymethane-induced
murine colon cancer (Dixon et al, 1998), and transgenic mice over-
expressing CDC25B show enhanced tumorgenicity on DMBA
(9,10-dimethyl-1, 2-benzanthracene) treatment (Yao et al, 1999). 
Disorders of the cell cycle and cell cycle-regulating molecules
are characteristics of cancer cells. In squamous cell carcinoma of
the oesophagus, such disorders are concentrated at the G1 check-
point, where amplification of cyclin D1 and loss of Rb, p16INK4 and
p27KIP1 are frequently observed. We have found disorders of these
molecules in more than 80% of oesophageal SCCs (squamous cell
carcinomas) (Shamma et al, 1998). Some of these disorders greatly
affect the clinical outcome, independently of other clinico-patho-
logical parameters, and have been found to be associated with
sensitivity for chemotherapy and/or radiation therapy via induction
of tumour cell apoptosis (Coco Martin et al, 1999; Fukuoka et al,
1996; Kokunai and Tamaki, 1999; Warenius et al, 1996). 
In the present study, we investigated the implication of the pres-
ence of CDC25 phosphatases in human oesophageal cancers by
immunohistochemistry and molecular biology, and found that
CDC25A over-expression is more strongly associated with
advanced clinical stage and poor patient prognosis than disorders
of other cell-cycle regulating molecules. 
MATERIALS AND METHODS 
Patients and tissue samples 
Surgical specimens were obtained from 100 patients (80 males 
and 20 females) who had squamous cell carcinoma of the oesoph-
agus and underwent subtotal oesophagotomy with lymph node
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dissection at the Department of Surgery II, Osaka University
Medical School between 1990 and 2000. The age of the patients
ranged from 45 to 80 years (mean: 61.2 ± 7.6 years). None had
received irradiation or chemotherapy before surgery nor had
haematogenic metastases at the time of surgery. The resected
surgical specimens were fixed in 10% formaldehyde, processed
through graded ethanol, and embedded in paraffin. A piece of each
tissue sample was immediately frozen in liquid nitrogen and stored
at – 80˚C until use for analyses by RT-PCR (reverse transcription
polymerase chain reaction) and immunoblotting. 
Antibodies 
The following antibodies were used in this study: rabbit polyclonal
anti-human CDC25A antibody (Santa Cruz Biotechnology, CA),
mouse monoclonal anti-human CDC25B antibody (Transduction
Laboratories, Lexington, KY), rabbit polyclonal anti-human
cyclin D1 antibody, M-20 (Santa Cruz Biotechnology, CA), mouse
monoclonal IgG against human Rb protein, G3-245 (Pharmingen,
San Diego, CA), rabbit polyclonal anti-human p16INK4 (anti-
serum), Catalog No. 15126E (Pharmingen), rabbit polyclonal anti-
human p27KIP1 antibody, C-19 (Santa Cruz Biotechnology, CA),
mouse monoclonal anti-human PCNA antibody, batch 107904
(Novacastra Laboratories, Newcastle, UK), mouse monoclonal
anti-human HSP27 antibody (G3.1; StressGen Biotechnologies
Corporation, Victoria, British Columbia, Canada) and mouse
monoclonal anti-human beta-actin antibody, A5441 (SIGMA, St.
Louis, MO). The final diluted concentrations were as follows:
anti-CDC25A, 0.5 mgm l –1; anti-CDC25B, 1.25 mgm l –1; anti-
cyclin D1, 0.5 mgm l –1; anti-Rb protein, 5 mgm l –1; anti-p16INK4,
400-fold dilution of the anti-serum; anti-p27KIP1, 2 mgm l –1; anti-
PCNA, 1mgm l –1; anti-human HSP27, 1000-fold dilution and anti-
human beta-actin, 5000-fold dilution. The lysate from Hela cells,
obtained from Transduction Lab., was used as a positive control
for CDC25B in western blot analysis (Gabrielli et al, 1996). 
Immunohistochemistry 
Sections 4 mm thick were deparaffinized in xylene, rehydrated and
boiled for antigen retrieval (Ciaparrone et al, 1998). Processes of
immunohistochemistry for CDC25A and CDC25B were performed
with a TeckMate Horizon automated staining system (DAKO) using
a Vectastain ABC-peroxidase kit (Vector Labs, Burlingame, CA), as
previously described (Okami et al, 1999). In the primary antibody
reaction, the slides were incubated with appropriate antibodies for 1
h at room temperature. Those for cyclin D1, Rb, p16INK4, and p27KIP1
were previously described (Shamma et al, 1998). 
Immunohistochemical assessment of CDC25A and
CDC25B 
Assessment of the staining was performed by two independent
observers (YD and KN) who had no knowledge of the tumour
stage or patient history. The expressions of CDC25A and CDC25B
were evaluated according to the frequency of positive staining in
the cytoplasm and/or nucleus of cancer cells. Since positive
staining of CDC25A was common but showed various frequencies
in oesophageal cancers, its expression was classified as positive
(+) in cases with more than 50% positive-stained cells, with other
samples being classified as negative (–). Nuclear expression of
CDC25A was evaluated and determined as positive when more
than 10% of the cancer cells showed obvious nuclear staining. In
the case of CDC25B expression, cases with more than 10% posi-
tive-stained cells were classified as positive (+) and others as
negative (–). Evaluation criteria of cyclin D1, Rb, p16INK4, and
p27KIP1 were previously described (Shamma et al, 1998). 
Western blot analysis for CDC25A and CDC25B 
Approximately 100 mg of each sample was homogenized in 1 ml
lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40)
with protease inhibitor (1 mM PMSF, 10 mg ml–1 aprotinin, 
10 mg ml–1 leupeptin). The homogenate was centrifuged at 
15 000 rpm for 20 min at 4˚C. The resulting supernatant was
collected and the total protein concentration was determined by
the Bradford protein assay (Bio Rad, CA). 
Cell fractination was also performed for western blotting of
CDC25A. Fifty mg of tissue sample was soaked in 500 ml of hypo-
tonic buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 300 mM
sucrose, 1 mM EDTA, 0.25 mM EGTA, 0.1 mM DTT, 1 mM
PMSF, 100 mg ml–1 leupeptin, 0.5% NP-40, pH 7.9) for 30 min and
centrifuged at 15 000 rpm for 5 min at 4˚C. The supernatant was
collected for cytoplasmic protein. The pellet was soaked in 300 ml
hypertonic buffer (20 mM HEPES, 1.5 mM MgCl2, 0.5 M NaCl,
25% Glycerol, 1 mM EDTA, 0.1 mM DTT, 1 mM PMSF, 
100 mg ml–1 leupeptin, 0.5% NP-40, pH 7.9) for 30 min and
centrifuged at 15 000 rpm for 5 min at 4˚C. The supernatant was
collected for nuclear protein. Each fraction protein concentration was
determined as described above. Western blotting was performed, as
described previously (Yamamoto et al, 1999). Briefly, 100 mg of the
total protein was subjected to 10% polyacrylamaide gel elec-
trophoresis (PAGE) followed by electroblotting onto a polyvinyli-
dene difluoride (PVDF) membrane. After blocking in 5% skim milk,
the membrane was incubated with 0.5 mg ml–1 CDC25A or with 1 mg
ml–1 CDC25B antibody, followed by incubation with 0.5 mg ml–1 of
secondary antibody (anti-rabbit IgG horseradish peroxidase conju-
gate for CDC25A and anti-mouse IgG horseradish peroxidase conju-
gate for CDC25B, Promega Corp., Madison, WI). For detection of
the immunocomplex, the ECL western blot detection system
(Amersham, Aylesbury, UK) was used. An equal amount of protein
from each tissue extract was confirmed by immunoblot for beta-actin
and gel staining with Coomassie blue. HSP27, which is located only
in the cytoplasm, served as a control for cell fractionation. 
RNA extraction and RT-PCR analysis 
Total RNA was extracted with a single-step method using
TRIZOL reagent (Life Technologies, Inc., Gaithersburg, MD) and
complementary DNA (cDNA) was generated using avian
myeloblastosis virus reverse transcriptase (Promega, Madison,
WI), as previously described (Gabrielli et al, 1996). Briefly, 1 mg
of RNA was incubated at 70˚C for 5 min and then put on ice
before the addition of RT (reverse transcription) reaction reagents
with oligo-(dT) 15 priming. The RT reaction was performed at
42˚C for 90 min, followed by heating at 95˚C for 5 min. 
Semi-quantitative analysis for the expression of CDC25A or
CDC25B mRNA was performed by the multiplex RT-PCR tech-
nique, using porphobilinogen deaminase (PBGD) (Chretien et al,
1988; Nagel et al, 1996) as the internal standard. To minimize the
inter-PCR difference, PCR was performed with PBGD and
CDC25A or CDC25B primers in identical tubes, under unsatu-
rated conditions, as described previously (Okami et al, 1999).414 K Nishioka et al
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PCRs were performed in a total volume of 25 ml reaction mixture
containing 1 ml of cDNA template, 1X Perking Elmer PCR buffer,
1.5 mM MgCl2, 0.8 mM deoxynucleotide triphosphates, 20 pmol
of each primer for CDC25A or CDC25B, and 4 pmol each for
PBGD, and 1 unit of Taq DNA Polymerase (AmpliTaq GoldTM,
Roche Molecular Systems, Inc., NJ). The primer sets of CDC25A
and CDC25B were designed to flank at least one intron and tested
to ensure amplification of only cDNA to avoid amplification of
any contaminating genomic DNA. We confirmed that the DNAs
obtained from normal volunteers were absent of PCR products.
The sequences of these PCR primers were as follows: 
CDC25A, (sense): 5¢-GAGGAGTCTCACCTGGAAGTACA-3¢
(NT 1297–1569 cDNA) and (antisense): 5¢-GCCATTCAAAA
CCAGATGCCATAA-3¢. CDC25B, (sense): 5¢-CACGCCCGT-
GCAGAATAAGC-3¢ (nt 1059–1475 cDNA) and (antisense): 5¢-
ATGACTCTCTTGTCCAGGCTACAGG-3¢. 
The primers for PBGD were synthesized as previously described
(Nagel et al, 1996). The size of the amplicons for CDC25A,
CDC25B, and PBGD were 272, 416, and 127 bp, respectively. The
PCR conditions were as follows: initial denaturing at 95˚C for 12
min, followed by 35–40 cycles of 95˚C for 1 min, 62˚C for 1 min
and 72˚C for 1 min, before a final extension at 72˚C for 10 min. A
10 ml portion of each PCR product was electrophoresed on 2%
agarose gel, and stained with ethidium bromide. The PCR products
were scanned by densitometry. 
Statistical analysis 
Statistical analysis was performed using the Statview J-5.0
program (Abacus Concepts, Inc. Berkeley, CA). Twelve patients
who underwent non-curative surgery with residual tumor (R2)
(TNM classification, 1997), 8 patients who could not be
followed during the postoperative follow-up and 10 patients who
had undergone surgery within the prior 6 months, were excluded
from survival analysis. For the remaining 70 patients, the
follow-up period ranged from 6.1 months to 79.7 months
(average 20.4 months). The Kaplan–Meier method was used to
estimate death from oesophageal cancer and the log-rank test
was used to estimate statistical significance. A Cox proportional
hazards model was used to assess the risk ratio with simulta-
neous contribution from several covariates. The associations
between the discrete variables were assessed using Fisher’s
exact test. Mean values were compared using the Mann-Whitney
test. Differences causing P values < 0.05 were accepted as statis-
tically significant. 
RESULTS 
Immunohistochemical expression of CDC25A and
CDC25B 
In the non-cancerous stratified squamous epithelium of the esoph-
agus, CDC25A staining was weakly observed in the nuclei of
C D
A B
Figure 1 Immunohistochemical staining of CDC25A in normal oesophageal epithelium (A) and squamous cell carcinomas of the oesophagus (B, C, D).
Oesophageal cancers were classified as negative (B) and positive (C, D) according to the frequency of stained cells, and sometimes accompanied by nuclear
CDC25A expression. (D) Original magnification ´ 100 (A) ´ 200 (B) and ´ 400 (C, D). Bars: 100 mm CDC25A as a novel prognostic indicator 415
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parabasal layer cells, while CDC25B was faintly detected in the
cytoplasm of spinous layer cells (Figures 1A and 2A). In the inter-
stitial tissue, both were weakly expressed in the germinal centre of
lymph follicles. In most oesophageal cancer cells, CDC25A was
strongly stained in the cytoplasm, sometimes accompanied by
nuclear staining (Figures 1B, C and D). CDC25B was frequently
observed to be strong in the cytoplasm of cancer cells, but not
detectable in some tumours (Figures 2B and C). CDC25B expres-
sion was not apparent in the nuclei of cancer cells and was some-
times stronger in the deep invading cells than in the superficial
cells (Figure 2D). The specificities of CDC25A and CDC25B
staining were confirmed by an absorption test in which each anti-
body was mixed with an excess amount of antigen. 
Expressions of CDC25A and CDC25B were evaluated
according to the frequency of positive stained cells. As shown in
Table 1, expression of CDC25A was more common than that of
CDC25B. Therefore, CDC25A expression was classified as posi-
tive (+) in 46 cases (46%), in which more than 50% of the cells
showed positive staining, while CDC25B expression was divided
at the cut-off line of 10% positive-stained cells, resulting in 48
cases (48%) being judged CDC25B positive (+). Nuclear staining
for CDC25A was observed in 51 cases (51%). However, the
frequency of nuclear CDC25A expression was not correlated with
that of cytoplasmic expression. 
Western blot and RT-PCR analysis for CDC25A and
CDC25B expression 
Western blot analyses for CDC25A and CDC25B protein (Figure
3) and cell fractination for CDC25A subcellular localization
(Figure 4) were performed using representative oesophageal
cancer specimens with various immunostaining patterns,
A B
C D
Figure 2 Immunohistochemical staining of CDC25B in the normal oesophageal epithelium (A) and squamous cell carcinomas of the oesophagus (B, C, D).
Oesophageal cancers were classified as negative (B) and positive (C, D) according to the frequency of stained cells. CDC25B expression was stronger in the
deep invading cells than in the superficial cells (D). Original magnification ´ 100 (A, D) ´ 200 (C) and ´ 400 (B). Bars: 100 mm 
Table 1 Immunohistochemical expression of CDC25A and CDC25B in oesophageal cancers 
Frequency of positively stained cells (%) 
0–10 10–50 50–80 80–100 Total 
CDC25A 11 43 38 8 100 
Nuclear CDC25A 0 25 (49%) 20 (39%) 6 (12%) 51 (100%) 
CDC25B 52 11 18 19 100 416 K Nishioka et al
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together with the corresponding non-cancerous mucosa. The
bands at 63 kD, which were confirmed to be CDC25B both by
positive control lysate of HeLa cells and by absorption tests
using its blocking peptide, were observed only in some cancer
tissues, and well correlated with their immunohistochemical
expression (Figure 3). In contrast, the 58 kD CDC25A bands,
which were also confirmed by the absorption tests, were ubiqui-
tously observed among cancerous and non-cancerous tissues
(Figure 3). CDC25A bands in oesophageal cancers were
frequently stronger than those in non-cancerous mucosa, in
agreement with the immunohistochemical evaluation results for
CDC25A. In the subcellular localization analysis (Figure 4),
normal mucosa mainly expressed CDC25A in the cytoplasm,
however tumour tissues frequently expressed a high amount of
CDC25A in the nuclear fraction, in agreement with the immuno-
histochemical evaluation results. 
CDC25A
CDC25B
Case 1 Case 2 Case 3 Case 4
T E 3 NT N T NT NT
Case 1 Case 2 Case 3 Case 4
HeLa N T N T N T N T
Figure 3 Immunoblot analysis of CDC25A and CDC25B protein in oesophageal cancer tissues (T) and adjacent normal oesophageal epithelium (N). Arrows
indicate the bands for CDC25A (58 kD) and CDC25B (63  kD). The amount of CDC25A in tumours is equivalent (case 1) or less (case 2), than that of normal
mucosa, while it is more than twice the amount in case 3 and case 4, according to densitometry measurements. CDC25B was not expressed in normal mucosa
or in the tumour tissue of case 1, while bands of CDC25B were apparent in the remaining tumour tissue samples. TE3, which expresses a high amount of
CDC25A in both cytoplasm and nucleus, and Hela, which expresses CDC25B, served as positive controls. Evaluations by immunoblot were consistent with
immunohistochemistry findings, led to negative (case 1 and case 2) and positive (case 3 and case 4) classifications for CDC25A and negative (case 1) and
positive (case 2, case 3 and case 4) classifications for CDC25B. Nuclear staining for CDC25A was observed in case 4, but not in the others 
Table 2 Relationship between CDC25s expression and clinico-pathological parameters 
CDC25A CDC25B 
Total (+) (–) P value (+) (–) P value 
Age (years) 63.2 ± 6.7 60.4 ± 7.8 0.1174 60.2 ± 7.5 62.5 ± 7.3 0.2059 
Gender 
Male 80 40 40 0.1085 36 44 0.2298 
Female 20 6 14 12 8
Histological type 
G1, G2 61 25 36 0.2081 31 30 0.4803 
G3, G4 39 21 18 17 22 
Depth of invasion 
pT1, pT2 48 16 32 0.0141 17 31 0.0155 
pT3, pT4 52 30 22 31 21 
Nodal status 
pN0 44 13 31 0.0034 14 30 0.0041 
pN1 56 33 23 34 22 
TNM stage 
I II 43 12 31 0.0016 14 29 0.0073 
III IV 57 34 23 34 23 
Tumour size (mm) 67.8 ± 26.8 45.8 ± 22.6 0.0007 56.9 ± 20.7 51.9 ± 30.6 0.4515 CDC25A as a novel prognostic indicator 417
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RT-PCR analyses for CDC25A and CDC25B were quantified
by calculating the tumour/normal (T/N) ratio after adjustment with
respect to the bands of PBGD, a housekeeping gene. In agreement
with the immunoblot findings, the bands of CDC25A were recog-
nized in all cancers and non-cancerous tissues, while PCR prod-
ucts for CDC25B were recognized only in some tumour samples,
and not in non-cancerous mucosa (Figure 5). Three cases with
T/N ratios of more than 3.5 for CDC25A (case 1, 2, 4) and
three tumours with RT-PCR positive for CDC25B (case 2, 4, 5)
consistently exhibited positive (+) immunostaining for CDC25A
and CDC25B, respectively. 
Relationship of CDC25A and CDC25B expression with
clinico-pathological factors and other cell cycle
regulators 
Table 2 summarizes the relationship between CDC25A and
CDC25B expression and clinico-pathological factors. CDC25A
(+) was more frequent in T3,4 (TNM classification, 1997) cases
(30/52) than in T1,2 cases (16/48), and in patients with lymph
node metastasis (33/56) than in those without it (13/44). Thus
there was a strong positive correlation between CDC25A expres-
sion and depth of invasion (P = 0.0141), nodal status (P = 0.0034)
and TNM stage (P = 0.0016). CDC25B displayed the same rela-
tionship with depth of invasion (P = 0.0155), nodal status 
(P = 0.0041) and TNM stage (P = 0.0073). Only CDC25A was
correlated with tumour size, as 45.8 ±22.6 mm and 67.8 ±26.8 mm
in negative and positive cases, respectively. Nuclear localization of
CDC25A was not associated with any of the clinico-pathological
factors (data not shown). 
Table 3 shows the association of CDC25A with CDC25B and
other cell cycle-regulating molecules, including cyclin D1, Rb,
p16INK4, p27KIP1 and PCNA, which we have reported to be impli-
cated in oesophageal carcinogenesis. There was no significant
correlation between CDC25A and CDC25B expression, as well as
other molecules. Also, there was no significant correlation
between CDC25B and these cell cycle-regulating molecules (data
not shown). 
Survival analysis 
The cumulative postoperative survival curves revealed that patients
with CDC25A (–) showed better prognosis than those with CDC25A
(+) (5-year survival 66.2% vs 23.9%, P = 0.0095) (Figure 6).
However, the difference between CDC25B (–) and (+) (5-year
survival 62.5 vs 18.7%) was not statistically significant (P = 0.0755).
Table 3 Relationship between CDC25A expression and other cell cycle
regulators 
CDC25A expression 
Positive Negative P value 
CDC25B 
Positive 25 23 0.2409 
Negative 21 31 
Cyclin D1*
Positive 16 18 0.9324 
Negative 24 26 
Rb*
Positive 32 33 0.5843 
Negative 8 11 
p16INK4*
Positive 17 22 0.4912 
Negative 23 22 
p27KIP1*
Positive 24 28 0.7318
Negative 16 16 
PCNA* 
Positive 18 26 0.1965 
Negative 22 18 
*Eighty-four cases were available for the immunohistochemical evaluation of
cyclin D1, Rb, p16INK4, p27KIP1, PCNA. 
Table 4 Prognostic factors in patients with squamous cell carcinoma of the oesophagus 
Univariate analysis Multivariate analysis 
RR 95%  CI  P value RR  95%  CI  P value 
CDC25A staining 
(–) 1 1
(+) 3.022  1.251–7.304  0.014  3.289  1.026–10.54  0.0451 
CDC25B staining 
(–) 1 
(+) 2.051  0.91–4.621  0.0831
Nodal status 
pN0 1  1 
pN1 2.502  1.382–4.528  0.0024  0.584  0.139–2.447  0.4616 
Depth of invasion 
pT1, pT2  1  1
pT3, pT4  2.322  1.311–4.111  0.0038  2.901  0.757–11.124  0.1203 
Tumour size(mm) 
50 > 1  1
50 ≤ 2.752 1.087–6.966  0.0327  1.815  0.421–7.833  0.424 
p27KIP1
(+) 1  1
(–) 2.017  1.144–3.555  0.0153  2.120  0.845–5.319  0.1094 
RR; risk ratio, CI; confidence interval, (–); negative, (+); positive. 418 K Nishioka et al
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Using the Cox proportional hazard model, the depth of invasion,
lymph node metastasis, TMN stage and p27KJP1, which was revealed
to be a significant prognostic factor in our previous study (Shamma et
al, 1998), were found to be significant prognostic factors by
univariate analysis (Table 4). Multivariate analysis revealed only
CDC25A status to be an independent prognostic factor (P = 0.0451,
risk ratio 3.289), with the others not being statistically significant.
Nuclear localization did not affect postoperative survival (Figure 6). 
DISCUSSION 
This is the first study to examine the expression of CDC25A and
CDC25B in human oesophageal cancer tissues. We found over-
expression of protein and mRNA of both CDC25A and CDC25B,
and this is consistent with previous studies on head and neck cancers
(Gasparotto et al, 1997) and non-small cell lung cancers (Wu et al,
1998). 
CDC25A
HSP27
Tumour 1 Tumour 2 Tumour 3
P . C . CNCNCN CN
Normal
Figure 4 Subcellular localization of CDC25A protein. Tissue samples were separated into cytoplasmic (C) and nuclear (N) fractions and subjected to
immunoblotting of CDC25A. Recombinant CDC25A was used for positive control (PC), and HSP27, which is expressed mostly in cytoplasm, was used as the
control for cell fractionation. Normal mucosa expressed CDC25A mainly in the cytoplasm, but tumour tissues expressed various amounts of nuclear CDC25A
accompanied by cytoplasmic CDC25A. Immunohistochemical evaluation for CDC25A in each tumour gave results which were negative (Tumour 1), positive
(Tumour 2), and positive with nuclear staining (Tumour 3) 
CDC25A
PBGD
CDC25B
PBGD
Case 1 Case 2 Case 3 Case 4
N TNT NTN T
Case 5
Case 1 Case 2 Case 3 Case 4 Case 5
NT
N TNT NTN TN T
Figure 5 Semiquantitative RT-PCR analysis of CDC25A and CDC25B m-RNA expression in oesophageal cancer tissues (T) and the adjacent normal
oesophageal epithelium (N). The co-amplified PBGD gene served as an internal control. Immunohistochemical evaluation in each case was classified as
negative (case 3 and case 5) and positive (case 1, case 2 and case 4) for CDC25A, and negative (case 1 and case 3) and positive (case 2, case 4 and case 5)
for CDC25B CDC25A as a novel prognostic indicator 419
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The CDC25A gene and CDC25B gene are located at 3p21 and
20p13, respectively, however, neither has been reported to be ampli-
fied in human oesophageal cancers. Moreover, although the latter
locus is amplified in non-small cell lung cancers, it has not been
associated with CDC25B over-expression (Wu et al, 1998). These
findings suggest that not gene amplification but some transcrip-
tional events are involved in protein and mRNA over-expression of
CDC25s. One of the key molecules involved in transcription is c-
myc, which strongly induces transcription of both CDC25A and
CDC25B (Galaktionov et al, 1996) in cell experiments, and is
frequently amplified in human oesophageal cancers (Lu et al,
1988) as well as other cancers in vivo. In non-Hodgkin lymphoma,
the mRNA expression of CDC25B, but not CDC25A, is associated
with c-myc overexpression (Hernandez et al, 1998). These findnds
suggest that over-expression of CDC25B may have been induced
by c-myc amplification in the present study for esophageal SCCs. 
Comparison of CDC25A and CDC25B showed that over-
expression of CDC25A is more frequent and ubiquitous, and that
there is no correlation between their expressions. These findings
are consistent with those of other studies, which simultaneously
analysed CDC25A and CDC25B mRNA expression (Gasparotto
et al, 1997; Kudo et al, 1997; Wu et al, 1998). CDC25A is
expressed in a positive feedback manner during the G1/S phase as
follows: CDC25A activates cyclin A/E-cdk2, resulting in release
of E2F, which again induces CDC25A transcription (Chen and
Prywes, 1999). Down-regulation by TGF-beta has been reported
as another mechanism for CDC25A over-expression in vivo (Kang
et al, 1999). These phenomena suggest that different regulation
systems are involved in CDC25A and CDC25B transcription. 
In the CDC25 family, the catalytic domain in the carboxyl
terminus is well preserved, but little homology is observed in the
amino-terminus domain, which is thought to be the regulatory
domain (Galaktionov et al, 1995; Nagata et al, 1991; Sadhu et al,
1990). This would cause a difference in the cellular localization of
CDC25A and CDC25B. Since CDC25A has a nuclear localization
signal in the N-terminus, nuclear staining is frequently observed.
However, the nuclear expression of CDC25A is not always corre-
lated with cytoplasmic expression and is not associated with
clinico-pathological factors or postoperative prognosis. In the case
of CDC25B, although its nuclear localization has been reported
during the cell cycle in the cultured cell lines, it was not observed
in human oesophageal cancers in this study nor in gastric cancers
in a previous study by Kudo et al (Kudo et al, 1997). Also, in
previous studies, we did not detect nuclear expression of CDC25B
in colon cancers (Takemasa et al, 2000) and hepatocellular carci-
nomas (unpublished observation by Yamamoto et al). Since a
nuclear export system is involved in CDC25B activation (Karlsson
et al, 1999), the CDC2/cyclin B complex may be de-phosphory-
lated by CDC25B in the cytoplasm at the G2 phase, and thereafter
be transferred to the nucleus in the mitotic phase. 
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Figure 6 Cumulative survival curves for oesophageal cancer patients classified according to CDC25A (A), CDC25B (B) and nuclear CDC25A (C) status
(Kaplan–Meier method) Interestingly, although there was no correlation between
CDC25A and CDC25B expression, both were correlated with
tumour invasion and metastasis. Moreover, since CDC25A was also
associated with tumour size, it may contribute to cancer progression
via tumour proliferation. During the cell cycle, the G1 checkpoint is
critical for oesophageal cancers, therefore not only CDC25A, but
also other G1-regulating molecules, including cyclin D1, Rb,
p16INK4 and p27KIP1, are implicated (Shamma et al, 1998). The
expression of CDC25A was not associated with those of the other
G1-regulating molecules. Also, CDC25A expression was associated
with postoperative prognosis, and surprisingly, multivariate analysis
revealed that it was the only independent prognostic factor among
clinico-pathological factors, such as depth of invasion, lymph node
metastasis and p27KIP1 expression. Recently, competitive interaction
between CDC25A and p21cip1 to cyclin-cdk complex has been
demonstrated (Partha et al, 1997). However, in our preliminary
study, p21cip1 expression was more strongly affected by the status of
both p53 and tumour differentiation than that of CDC25A (data not
shown). It would be of interest to investigate the relationship
between p21cip1 and CDC25A in other cancers. 
The effect of CDC25B status on postoperative survival was not
statistically significant. Theoretically, CDC25B over-expression
accelerates cell proliferation, and therefore would be a poor prog-
nostic indicator. Recently, we found that CDC25B over-expression
is associated with a high sensitivity for chemoradiation therapy
through G2/M arrest (Miyata et al, 2000). Postoperative adjuvant
therapy, including chemotherapy and radiation therapy, was
performed for 26 patients of this series. We found no significant
results for the clinical benefit of adjuvant therapy in this small
number of patients, however, with a larger cohort, some influence
of CDC25B status may be found. 
In the present study, we used different cut-off lines for CDC25A
(50%) and CDC25B (10%). When we used other cut-off lines for
the data in Table 1, such as 10% or 80% for CDC25A or 50% or
80% for CDC25B, the differences in postoperative survival were
smaller and not statistically significant, although the trend was the
same. The cut-off lines in this study well reflect the biological
properties of the molecules. The other cut-off lines led to biased
separations, in which one side included too few cases to allow
statisticaly significant differences. 
We have presented here the significance of CDC25A as a novel
prognostic factor in human oesophageal cancers. This study is a
start toward elucidating the implication of CDC25s in clinical
cancer treatment. 
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